02196 FOSUN PHARMA
- 15.360
- +0.300+1.99%
FOSUN PHARMA News
Shanghai Fosun Pharma Announces Drug Registration Acceptance
Fosun Pharma (02196): The pharmaceutical registration applications for Levofloxacin Injection and Acyclovir Injection have been accepted by the National Medical Products Administration.
Fosun Pharma (02196) announced that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the 'Company'...
Express News | Shanghai Fosun Pharma - Drug Registration Applications of Levofloxacin Injection and Cytarabine Injection by Units Accepted by Nmpa
Fosun Pharma (600196.SH): A subsidiary holding company received acceptance of pharmaceutical registration application.
GraceUnion November 4th | Fosun Pharma (600196.SH) announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd.'s Levofloxacin Injection (referred to as "New Drug 1") and its holding subsidiary Gismei (Wuhan) Pharmaceutical Co., Ltd.'s Azacitidine Injection (referred to as "New Drug 2") have each had their pharmaceutical registration applications accepted by the National Medical Products Administration. Both New Drug 1 and New Drug 2 are chemical drugs independently developed by this group (i.e. the Company and its holding subsidiaries/units). New Drug 1 is intended for the following mild, moderate, and severe infections caused by sensitive bacteria: (1) Hospital-acquired pneumonia.
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Earnings Update: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Historically the most 'competitive'? The Tenth Batch of National Procurement Pharmaceutical Catalog Is Officially Announced with one type having up to 31 companies competing.
①This afternoon, the National Pharmaceutical Joint Procurement Office officially announced the tenth batch of nationally purchased pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Several industry insiders have stated that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
Fosun Pharma (02196) intends to provide joint liability guarantee for special M&A loans to Fosun Pharma Industry not exceeding 0.16 billion yuan.
Fosun Pharma (02196) announced that the company plans to apply for a loan denominated in Renminbi from Shanghai Rural Commercial Bank for its subsidiary Fosun Health...
fosun pharma (02196): rosethriptyline hydrochloride acetate for injection approved for marketing.
Fosun Pharma (02196) announced that its controlling subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., the injection use hydrochloride rosary...
Express News | Shanghai Fosun Pharma - Unit Got Marketing Registration Approval From Nmpa for Roxatidine Acetate Hydrochloride for Injection
Fosun Intl (00656): Focusing on core business shows results. The medical and consumer sectors are improving, increasing the certainty of performance.
fosun intl accelerates the realization of core business value.
Fosun Pharma Announces 2024Q3 Financial Results
Press Release: Fosun Pharma Announces 2024Q3 Financial Results
zheshang: Continuous realization of technological innovation upgrade driving the continuous improvement of performance expectations for innovative drugs and industry chain.
The commercialization period of innovative drugs in the industry chain, driven purely by incremental value, is entering the phase of realization. The scarce incremental prosperity of the pharmaceutical sector continues to rise, with increasing international competitiveness, and there is still room for upward valuation.
HK Stock Market News | Some pharmaceutical stocks rose in early trading, as the national medical insurance negotiations are expected to start soon. Institutions say that sector catalyst events will be intensive in the fourth quarter.
Some pharmaceutical stocks rose in the morning session, as of the time of publication, Remegen (09995) rose by 8.73%, to 15.7 Hong Kong dollars; Keji Pharmaceutical-B (02171) rose by 6.47%, to 15.7 Hong Kong dollars; Aneuro-B (01952) rose by 2.11%, to 31.5 Hong Kong dollars; Fosun Pharma (02196) rose by 3.7%, to 15.12 Hong Kong dollars.
Hong Kong stock unusual movement | Fosun Pharma (02196) rose more than 4% after the performance. Third-quarter revenue, net profit attributable to parent after deduction of non-recurring items increased year-on-year in unison.
Fosun Pharma (02196) rose more than 4% after the performance announcement, up 4.66% to HKD 15.28 as of press time, with a turnover of 58.6756 million Hong Kong dollars.
Fosun Pharmaceuticals 2024 Third Quarter Report
FOSUN PHARMA: 2024 THIRD QUARTERLY REPORT
Fosun Pharma (600196.SH): The net income for the first three quarters was 2.011 billion yuan, a year-on-year decrease of 11.9%.
Gelonghui October 29th | Fosun Pharma (600196.SH) announced that the company achieved revenue of 30.912 billion yuan in the first three quarters, a year-on-year increase of 0.7%; net income attributable to shareholders was 2.011 billion yuan, a year-on-year decrease of 11.9%; non-net profit attributable to shareholders was 1.836 billion yuan, a year-on-year increase of 24.6%.
Fosun Pharma's third quarter revenue and net income attributable to parent company excluding non-recurring items in 2024 increased at the same rate year-on-year, with innovative research and development investment exceeding 3.9 billion yuan.
Innovation and research and development, fosun pharma continues to focus on its advantageous pipeline, achieving efficient results transformation and continuous implementation of innovative products.
Analysis
Price Target
No Data
No Data